Teladoc Health, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on October 29, 2026, covering the fiscal quarter ended September 30, 2026.

Key Highlights

  • Quarterly revenue: The company reported revenue of $605,102 thousand for the three months ended September 30, 2026, compared with $626,439 thousand for the same period in 2025.
  • Net loss: Net loss for the third quarter of 2026 was $26,934 thousand, or $0.15 per basic and diluted share, versus a net loss of $49,507 thousand, or $0.28 per share, in Q3 2025.
  • Nine-month revenue: For the nine months ended September 30, 2026, the company reported revenue of $1,825,874 thousand, down from $1,887,708 thousand in the prior-year period.
  • Cash position: Cash and cash equivalents stood at $849,909 thousand as of September 30, 2026, up from $781,084 thousand at December 31, 2025.
  • Convertible senior notes reclassified: Convertible senior notes, net of $997,593 thousand were classified as current liabilities as of September 30, 2026, compared with $994,925 thousand classified as non-current at December 31, 2025.
  • Shares outstanding: As of October 23, 2026, the registrant had 182,293,675 shares of common stock outstanding.
  • Accumulated deficit: The accumulated deficit reached $16,559,901 thousand as of September 30, 2026, compared with $16,430,222 thousand at December 31, 2025.

Teladoc Health Financial Results for the Quarter Ended September 30, 2026

According to the filing, Teladoc Health (NYSE:TDOC) reported third-quarter 2026 revenue of $605,102 thousand, a decrease from $626,439 thousand in the third quarter of 2025. Total costs and expenses for the quarter were $633,201 thousand, resulting in a loss from operations of $28,099 thousand, compared with a loss from operations of $51,962 thousand in the year-ago quarter. The company recorded a net loss of $26,934 thousand for Q3 2026, an improvement from the $49,507 thousand net loss reported in Q3 2025.

For the nine months ended September 30, 2026, the filing disclosed revenue of $1,825,874 thousand versus $1,887,708 thousand for the same period in 2025. The nine-month net loss was $129,679 thousand, or $0.72 per basic and diluted share, compared with a net loss of $175,179 thousand, or $1.00 per share, in the prior-year period. The company reported no goodwill impairment charge in either the three or nine months ended September 30, 2026, whereas the prior-year periods included charges of $12,625 thousand and $71,763 thousand, respectively.

The balance sheet as of September 30, 2026 showed total assets of $2,775,075 thousand and total liabilities of $1,480,352 thousand. Notably, the filing reflected a reclassification of convertible senior notes, net from non-current to current liabilities, with $997,593 thousand presented as current as of September 30, 2026. Total stockholders' equity was $1,294,723 thousand at quarter end. Stock-based compensation for the nine-month period was $36,807 thousand, according to the statement of stockholders' equity.

What Was Disclosed

Teladoc Health's Form 10-Q for the period ended September 30, 2026 disclosed quarterly and nine-month financial results, balance sheet data including the reclassification of convertible senior notes to current liabilities, and share count information as of October 23, 2026.